{
    "clinical_study": {
        "@rank": "158140", 
        "arm_group": {
            "arm_group_label": "MabThera/Rituxan", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of MabThera/Rituxan in patients with\n      relapsed low-grade centroblastic centrocytic non-Hodgkin`s lymphoma. Patients will receive\n      once-weekly intravenous MabThera/Rituxan for 4 weeks; responding patients will be treated a\n      second time in case of relapse (defined as progression after complete or partial response).\n      The anticipated time on study treatment is <3 months."
        }, 
        "brief_title": "A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "condition": "Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients >= 18 years of age;\n\n          -  centrocytic centroblastic non-Hodgkin`s lymphoma stage III-IV;\n\n          -  relapse after chemotherapy (with or without interferon maintenance therapy).\n\n        Exclusion Criteria:\n\n          -  primary refractory lymphomas;\n\n          -  more than 3 relapses of centroblastic centrocytic non-Hodgkin`s lymphoma;\n\n          -  clinically significant cardiac disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998893", 
            "org_study_id": "M39004"
        }, 
        "intervention": {
            "arm_group_label": "MabThera/Rituxan", 
            "description": "375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse", 
            "intervention_name": "rituximab [MabThera/Rituxan]", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "zip": "91054"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grenzach-wyhlen", 
                        "country": "Germany", 
                        "zip": "79639"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "G\u00f6ttingen", 
                        "country": "Germany", 
                        "zip": "37075"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "30625"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Homburg/saar", 
                        "country": "Germany", 
                        "zip": "66424"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "50924"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany", 
                        "zip": "80336"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany", 
                        "zip": "81377"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenster", 
                        "country": "Germany", 
                        "zip": "48129"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stuttgart", 
                        "country": "Germany", 
                        "zip": "70376"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "T\u00fcbingen", 
                        "country": "Germany", 
                        "zip": "72076"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Response in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma After Treatment With Anti-CD20 Antibody IDEC C2B8 (MabThera)", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Efficacy: Clinical response (complete or partial remission)", 
            "safety_issue": "No", 
            "time_frame": "approximately 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998893"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }, 
            {
                "measure": "Efficacy of re-treatment of responding patients, in case of disease progression: Clinical response", 
                "safety_issue": "No", 
                "time_frame": "approximately 1 year"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 8 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 1997", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}